Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
